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Abstract: Systemic inflammation is an integral part of chronic obstructive pulmonary disease (COPD),
and air pollution is associated with cardiorespiratory mortality, yet the interrelationships are not
fully defined. We examined associations between nitrogen dioxide (NO2) exposure (as a marker of
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traffic-related air pollution) and pro-inflammatory cytokines, and investigated effect modification
and mediation by post-bronchodilator airflow obstruction (post-BD-AO) and cardiovascular risk.
Data from middle-aged participants in the Tasmanian Longitudinal Health Study (TAHS, n = 1389)
were analyzed by multivariable logistic regression, using serum interleukin (IL)-6, IL-8 and tumor
necrosis factor-α (TNF-α) as the outcome. Mean annual NO2 exposure was estimated at residential
addresses using a validated satellite-based land-use regression model. Post-BD-AO was defined
by post-BD forced expiratory ratio (FEV1/FVC) < lower limit of normal, and cardiovascular risk
by a history of either cerebrovascular or ischaemic heart disease. We found a positive association
with increasing serum IL-6 concentration (geometric mean 1.20 (95% CI: 1.1 to 1.3, p = 0.001) per
quartile increase in NO2). This was predominantly a direct relationship, with little evidence for
either effect modification or mediation via post-BD-AO, or for the small subgroup who reported
cardiovascular events. However, there was some evidence consistent with serum IL-6 being on the
causal pathway between NO2 and cardiovascular risk. These findings raise the possibility that the
interplay between air pollution and systemic inflammation may differ between post-BD airflow
obstruction and cardiovascular diseases.
Keywords: nitrogen dioxide; traffic-related air pollution; interleukin; tumor necrosis factor-α;
systemic inflammation; airflow obstruction
1. Introduction
In 2012, the World Health Organization (WHO) attributed exposure to outdoor air pollution as
the cause for 389,000 premature deaths related to chronic obstructive pulmonary disease (COPD) [1].
The corresponding air pollution-related estimate that related to ischaemic heart disease and stroke
was five-fold higher, contributing to 72% of the 3 million premature deaths worldwide [2]. A recent
meta-analysis of 13 studies from across North America, Europe and Asia has shown a modest increase
in the relative risk (RR) of respiratory mortality with increasing chronic exposure to nitrogen dioxide
(NO2) (RR 1.02 (95% confidence interval (CI): 1.02–1.03) per 10 µg/m3 (or equivalent to per 5.32 ppb
increase)). This estimate comparable to the major air pollutant, particulate matter less than 2.5 µm
in diameter (PM2.5) (RR 1.05 (1.01–1.09) per 10 µg/m3) [3]. In this same meta-analysis, the positive
association between NO2 concentration and cardiovascular (CV) mortality was significantly stronger
than for respiratory mortality, in spite of marked heterogeneity between studies [3].
Systemic oxidative stress and inflammation have been implicated as a potential biological
pathway of pollution-related cardiovascular effects. This process originates in the lung and especially
involves the pro-inflammatory cytokines, interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) [4].
Epidemiological research has found only moderate evidence for a systemic inflammatory response
to traffic-related air pollution (TRAP) given a predominance of studies that addressed short-term
exposures to PM2.5 [5]. As a gaseous air pollutant, nitrogen dioxide (NO2) is regarded as a strong marker
for air pollution primarily generated from combustion including motor vehicles, biomass burning, airports
and industry [6,7]. Associations with NO2 exposure were not reported by the Harvard Six Cities Study,
a major longitudinal population-based study that has provided strong evidence to support a causal
relationship between PM2.5 and cardiovascular risk [5,8,9]. The epidemiological data regarding the
relationship between NO2 exposure and chronic obstructive pulmonary disease (COPD), an inflammatory
lung condition that is characterized by progressive airflow obstruction (AO), are limited [10].
Of the endogenous pro-inflammatory cytokines, IL-6 is a key player, particularly as the
primary inducer of C-reactive protein (CRP). Although neither are routinely measured as part of
risk prediction for coronary heart disease (CHD) [11], CRP (and IL-6 in unadjusted models) are
associated with an increased CHD risk [12]. IL-6 regulates many pathways involved in the acute phase
response and adaptive immunity [13], and can be a marker of COPD progression [14–16], especially
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when persistently elevated in people with otherwise stable disease [15]. A recent meta-analysis
of 33 individual studies found increased serum IL-6 among people with COPD compared with
controls [17]; however, there was evidence of publication bias and no account for diurnal variation [18]
or smoking status [19]. While TRAP might have direct effects on cardiorespiratory disease and IL-6
separately, it might also be possible that CV disease and/or COPD influence IL-6 levels following TRAP
exposure as an indirect effect. In other words, CV disease and/or COPD may in part mediate an increase
in serum IL-6 in response to higher NO2 exposures and which, in turn, might adversely influence
subsequent cardiorespiratory outcomes. In addition to IL-6, the roles of other classical pro-inflammatory
cytokines such as IL-8 and TNF-α in these interactions are unknown, although notably, COPD patients
have been shown to have lower levels of these cytokines than smokers without COPD [15].
Using data from middle aged participants of the fifth decade follow-up of the Tasmanian
Longitudinal Health Study (TAHS), we aimed to clarify interrelationships between NO2, systemic
cytokines and specific cardiorespiratory condition by means of: (A) examining cross-sectional
relationships between NO2 exposure and the pro-inflammatory cytokines, IL-6, IL-8 and TNF-α;
and (B) examining for effect modification and/or mediation by post-bronchodilator (BD)-AO and
cardiovascular disease.
2. Results
2.1. Characteristics of TAHS Participants
Clinical characteristics and lung function data for the 1389 laboratory study participants have
been published previously [20]. Briefly, the mean age (standard deviation (SD)) was 44.9 [0.85] years
and 51% were male. This group was enriched for asthma-ever, wheezy breathing and/or chronic
bronchitis, with one-quarter reporting asthma symptoms or medication use within the last 12 months
(n = 335). Over half were ever-smokers (57%, n = 804), of whom 59% (n = 457) had smoked for at least
ten pack-years. The criterion for post-BD-AO was met by 9.25% (n = 123), for whom mild, moderate
and severe airflow obstruction was identified for 77% (n = 95), 10% (n = 12) and 13% (n = 16) of
participants, respectively.
Of these participants with post-BD-AO of any severity, 87 (71%) reported cough, wheeze and/or
sputum expectoration; 71 (58%) had a 10-pack-year smoking history; and 66 (55%) had either asthma
symptoms or had taken asthma medication within the last 12 months. Of the 828 participants of the
subsequent laboratory visit, only 2.2% (19/828) reported a history of CVD, of whom 12 (63%) reported
ischaemic heart disease and seven (37%) reported cerebrovascular disease.
Descriptive statistics for participants with complete data have been summarized in Table 1,
stratified by the presence or absence of post-BD-AO. Expected differences in ventilatory function and
cumulative smoking history were seen; otherwise, variations in annual mean NO2 and measured
cytokine concentrations were not statistically significant.
Table 1. Characteristics of the TAHS laboratory study participants, by post-bronchodilator
airflow obstruction.
Participant Characteristic
TAHS 5th Decade Laboratory Study
Post-BD Airflow Obstruction (n = 973) 1
Yes (n = 97) No (n = 876) p-Value
Demographic and other features
Age in years (mean (SD)) 44.9 (0.8) 44.9 (0.9) 0.153
Sex (n, % male) 50 (52) 438 (50) 0.773
BMI categories (kg/m2)
Underweight (<18.5) 1 (1) 3 (0.3) 0.315
Normal (18.5–24.9) 30 (31) 262 (30) 0.835
Overweight (25–29.9) 36 (37) 359 (41) 0.462
Obese (≥30) 30 (31) 252 (29) 0.498
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Table 1. Cont.
Participant Characteristic
TAHS 5th Decade Laboratory Study
Post-BD Airflow Obstruction (n = 973) 1
Yes (n = 97) No (n = 876) p-Value
Cigarette smoking
None 21 (22) 389 (45) <0.001
Past, <20 pack years 16 (17) 211 (24) 0.107
Past, ≥20 pack years 4 (4) 47 (5) 0.624
Current, <20 pack years 17 (18) 115 (13) 0.206
Current, ≥20 pack years 37 (39) 109 (13) <0.001
Annual mean NO2 exposure
Predicted ppb (median, IQR) 4.1 (3.5, 5.9) 4.2 (3.5, 5.6) 0.733
Per quartile (median, IQR)
1 (lowest) 3.1 (2.8, 3.5) 3.1 (2.8, 3.4) 0.727
2 3.8 (3.7, 4.1) 3.9 (3.7, 4.1) 0.668
3 4.7 (4.6, 5.1) 4.9 (4.6, 5.4) 0.350
4 (highest) 6.7 (6.1, 7.3) 7.1 (6.3, 9.4) 0.066
Post-BD spirometry 2
FEV1 (L) 2.84 (0.7) 3.47 (0.7) <0.001
z-score −1.44 (1.1) 0.015 (1.0) <0.001
FVC (L) 4.45 (1.1) 4.34 (0.9) 0.542
z-score +0.152 (1.1) 0.008 (0.9) 0.258
FEV1/FVC (ratio) 63.8 (7) 80.2 (4.7) <0.001
z-score −2.37 (0.7) −0.041 (0.8) <0.001
Serum cytokine concentrations [GM 95% CI] pg/mL †
Interleukin-6 13.9 (12.2, 15.7) 12.1 (8.2, 17.9) 0.795
Interleukin-8 275 (244, 308) 353 (245, 509) 0.861
Tumor necrosis factor-α 6.8 (6.5, 7.2) 6.1 (5.2, 7.3) 0.082
Definition of abbreviations: BD, bronchodilator; BMI, body mass index; CI, confidence interval; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; GM, geometric mean; IQR, interquartile range; pg/mL,
picograms per milliliter; ppb, parts per billion; NO2, nitrogen dioxide; TAHS, Tasmanian Longitudinal Health
Study. 1 Participant numbers by complete case analysis with the following exclusions: NO2 not available (n = 64);
no biospecimen (n = 214) or blood collection time recorded (n = 97); pack-years not recorded (n = 28); technically
unacceptable spirometry (n = 60). 2 a z-score is the deviation from the mean predicted value expressed as standard
deviations (SD), where 95% of normally distributed data lies between −1.96 SD and +1.96 SD.
2.2. Main Association between NO2 Exposure and Cytokines
For all participants, increasing annual mean NO2 exposure when expressed as quartiles was
associated with increasing concentrations of serum IL-6 (Table 2, p-for-univariable trend = 0.012).
Compared with participants exposed to the lowest quartile of annual mean NO2, those exposed to the
second highest and highest quartiles had higher serum IL-6 concentrations with the ratio of geometric
mean (GM) estimated at 1.46 and 1.71, respectively. When quartiles of NO2 exposure were expressed
continuously, the estimate for serum IL-6 per quartile increase in annual mean NO2 concentration was
GM 1.20 (95% CI: 1.1 to 1.3, p = 0.001).
Table 2. Dose–response relationship between annual mean NO2 exposure and serum interleukin-6
concentrations for all participants.
Annual Mean NO2 Exposure Serum Interleukin-6 (95% CI)
p-Value
Quartile Range (ppb) n GM pg/mL Ratio of GM 1
1 2.41–3.54 340 11.4 (9.0 to 14.5) 1
2 3.54–4.30 340 12.9 (10.1 to 16.4) 1.16 (0.1 to 1.6) 0.400
3 4.31–5.81 338 16.0 (12.7 to 20.0) 1.46 (1.2 to 2.0) 0.024
4 5.81–23.8 337 17.5 (13.4 to 23.0) 1.71 (2.0 to 2.4) 0.003
Definitions of abbreviations: GM, geometric mean; NO2, nitrogen dioxide; ppb, parts per billion. 1 Multivariable
models were adjusted for body mass index, smoking status, pack-year group, sex, highest education, sampling
weights, blood collection time and delivery, seasons, batch (regression n = 973).
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However, main effects were not seen for either IL-8 or TNF-α (p-for-univariable trend = 0.852
and 0.710, respectively). When quartiles of NO2 exposure were expressed continuously, the adjusted
estimate per quartile increase in annual mean NO2 concentration was GM 1.06 ((95% CI: 0.95, 1.17),
p = 0.297), for serum IL-8, and GM 1.04 ((0.99, 1.1), p = 0.13) for TNF-α.
No interactions were seen between the effects of NO2 exposure and post-BD-AO on any of
the circulating pro-inflammatory cytokines (p-for-interaction > 0.174). There were no NO2-CVD
interactions (p-for-interaction > 0.178); however, only a few participants reported ischaemic
cardiovascular events in this age group (n = 19).
2.3. Mediation Analysis by Post-BD-AO
We used Causal Mediation Analysis [21] to determine the extent to which the total effect of
NO2 exposure on the pro-inflammatory cytokines was mediated by post-BD-AO, as measured by
a continuous variable. This analysis partitioned the total effect into an indirect effect of NO2 on cytokines
(NO2 acting through post-BD-AO and then post-BD-AO on cytokines) and a direct effect of NO2 on
cytokines (that did not act through changes in post-BD-AO induced by changes in NO2 exposure).
We observed only a direct relationship between NO2 exposure and serum IL-6 concentration, and
a negligible indirect effect through post-BD-AO (Table 3). The estimate suggested that around 17.5% of
the variation in IL-6 was explained by a direct effect from NO2 exposure. As there was little evidence
of a univariate relationship between serum IL-6 and post-BD-AO when lung function was analysed
as the outcome (p = 0.145), this suggested that it was unlikely that IL-6 was on the causal pathway
between NO2 exposure and post-BD-AO.
Table 3. Adjusted analyses for the NO2-cytokine relationship mediated by post-bronchodilator
airflow obstruction 1,2.
Mediation Analysis Effect
Post-BD Airflow Obstruction as the Mediator between NO2
and Serum Pro-Inflammatory Cytokines (Mean (95% CI))
IL-6 IL-8 TNF-α
Indirect Effect 0.0003 (−0.007, 0.008) 0.003 (−0.02, 0.01) −0.001 (−0.004, 0.01)
Direct Effect 0.175 (0.04, 0.30) 0.090 (−0.03, 0.20) 0.056 (0.003, 0.11)
Total Effect 0.175 (0.04, 0.30) 0.092 (−0.04, 0.20) 0.055 (0.001, 0.11)
% of Total Effect mediated 0.17% 2.92% 1.56%
Definition of abbreviations: AO, airflow obstruction; BD, bronchodilator; CI, confidence interval; NO2, nitrogen
dioxide. 1 NO2 exposure included as a categorical variable by definition (≤5.8, >5.8 ppb). 2 Adjustment included
body mass index, smoking status, pack-year group, sex, highest education, sampling weights, blood collection time
and delivery, season and batch.
In the absence of main effects between NO2 exposure and serum IL-8 and TNF-α, the mediation
effects on these cytokines were effectively negligible.
2.4. Mediation Analysis by Cardiovascular Disease (CVD)
We observed a modest direct relationship between NO2 exposure and serum IL-6 concentrations
(10.8% (95% CI: −6 to +26)), with a correspondingly minor indirect effect through CVD (0.6% (−1 to
+2.8)). In other words, of the total effect of NO2 exposure on serum IL-6 (11.4% (−7 to +29)),
the proportion of the total effect mediated was 0.054 or 5.4%. In separate univariate models when CVD
was analysed as the outcome, we additionally saw both serum IL-6 (OR 2.24 (95% CI: 1.2, 4.1, p = 0.008)
and IL-8 concentrations (OR 2.05 (1.1, 3.9), p = 0.029) associated with cardiovascular risk. However,
in the context of the main association between NO2 and serum IL-6 concentrations (Table 2), these
observations are consistent with circulating IL-6 being on the causal pathway between NO2 exposure
and cardiovascular risk (summarised in Figure A1).
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3. Discussion
Our cross-sectional analysis of the fifth decade follow-up of the TAHS longitudinal cohort has
shown a dose–response relationship between NO2 exposure and serum IL-6 levels at relatively low
levels of outdoor air pollution that was not evident for either IL-8 or TNF-α. However, there was little
evidence of either a modifying or mediating effect for the lung function criterion for diagnosing COPD,
post-BD-AO. Furthermore, the lack of association between IL-6 and post-BD-AO as the outcome
effectively excludes IL-6 being on the causal pathway. In contrast, our findings raise the possibility
that circulating IL-6 might be on the causal pathway between NO2 exposure and cardiovascular risk.
Activation of oxidative stress and the inflammatory response in both the pulmonary and systemic
compartments is one of the biological pathways postulated to mediate the adverse cardiovascular
effects of outdoor air pollution [4,5]. However, not all epidemiological data support this premise [22].
Our finding of a dose–response main association between NO2 exposure and serum IL-6 levels is
consistent with the linear relationship that has been seen for PM2.5 as adverse health effects occur
at low levels of exposure [8,9]. Although this relationship starts to become less steep at very high
concentrations of air pollutants, it becomes steeper at lower concentrations [23]. The lack of a currently
recognised threshold value reflects the 2005 WHO guidelines that aimed to limit particulate matter
concentrations to the lowest possible level [2].
Australia has relatively low levels of combustion-derived air pollution with the national
population-weighted average concentrations of NO2 ranging between 7.3 ppb (2006) and 6.3 ppb
(2011) [6]. In the present study, the positive association between NO2 concentration and serum IL-6 plus
the observation of IL-6 acting on cardiovascular risk favors a predisposition to cardiovascular events
for residents of more polluted areas [3,24]. In contrast, the relative lack of an effect mediated through
post-BD-AO (and cardiovascular risk) supports a predominant direct effect of NO2 on circulating
IL-6 levels, although a high proportion of the IL-6 variation is likely to represent unexplained factors.
While potential biological pathways with systemic IL-6 have been somewhat clarified using mediation
analysis, it is insufficient to explain the NO2-related increase in cardiorespiratory mortality [3,25].
For COPD patients, systemic inflammation has been identified to be an integral component of the
phenotype associated with accelerated lung function decline [26] and increased all-cause mortality [15].
However, the interplay between outdoor air pollution, post-BD airflow obstruction and inflammatory
processes has not been well characterized [27]. In a study of 242 clinically stable COPD patients, NO2
exposure was associated with elevated levels of CRP, but not its inducer IL-6 [10], although it was not
clear whether the blood sampling in the early morning hours spanned a period when IL-6 levels might
be quite variable as exact times were not given [18].
Whilst TRAP might indirectly influence systemic inflammation responses through a predisposition
to infection [28,29], our findings are consistent with a positive and direct association between NO2
exposure and systemic IL-6 concentrations at a population level. This relationship was not augmented
for the subgroup who fulfilled the lung function criterion for the clinical COPD phenotype, although
the majority of participants with post-BD-AO in the present study only had mild-to-moderate disease.
The lack of main effects for serum IL-8 and TNF-α may reflect the lower persistent levels seen in people
with COPD when compared with smokers who do not have the disease [15].
Our study has three main strengths: first, our measure of TRAP was derived from a validated
satellite-based land-use regression model for NO2 with national coverage [6], as ground-based
monitoring networks typically have sparse spatial coverage [30]. Second, our study was based
on prospectively collected data from a large population-based sample with a relatively low attrition
(around 33%) between 1968 (n = 8583) and 2004 (n = 5729), so estimates may represent the general
population after adjusting for sampling weights and smoking history. Third, although blood sampling
is typically taken in the early morning after fasting overnight [15] to minimize the diurnal variation,
the present study neither controlled for fasting nor for time of blood sampling. We still were able to
standardize cytokine concentrations based on the known diurnal variation of IL-6 in the regression
models [18], although this might have introduced some measurement bias.
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Our study also had limitations: firstly, the cross-sectional analysis has assessed for relevant
associations, but the lack of temporality does not support causal inference. We were unable to assess
accelerated FEV1 decline as an outcome, which is a key feature of the clinical COPD phenotype.
In addition, our annual NO2 exposure variable would have been strengthened if the measurement we
used encompassed a longer period of exposure, and if seasonal NO2 variation (in addition to season of
blood sampling) was taken into account [31]. Secondly, although we made some adjustment for time to
processing, and followed methods for optimizing serum storage duration and conditions [32,33], it is
probable that absolute cytokine concentrations were affected by a degree of degradation, absorption
and/or cellular production [34], especially with regard to TNF-α which has a half-life of only hours [35].
Thirdly, due to the relatively young age of participants, there were low case numbers in the group
reporting cardiovascular events which most likely resulted in insufficient power to examine for effect
modification of the NO2-IL-6 relationship. Fourthly, peripheral blood mononuclear cells (PBMCs)
were not isolated at the time of blood collection, and so additional information was not obtained to
more fully describe related immunological processes. Finally, as the laboratory participants resided in
urban areas of Australia and were almost exclusively Caucasian, this might limit the generalizability
of our findings to other populations.
4. Materials and Methods
4.1. Study Design and Population
The subjects were participants in the 5th decade follow-up of the population-based TAHS, which
commenced in 1968. The methods for the baseline and subsequent follow-up studies have been
published [20,32,36–40]. Briefly, the participants (otherwise known as “probands”) who were born in
1961 and schooled in Tasmania in 1968 (n = 8583 (99%)) were studied by questionnaires and spirometry
when seven-years old. Of the 7312 (85%) original probands who were retraced between 2002 and 2004,
a detailed postal survey was then conducted when the probands were aged in their early-to-mid forties.
A total of 5729 (78%) responded, representing two-thirds (67%) of the original cohort. Respondents
were chosen to participate in a clinical laboratory study based on either participation in multiple
follow-up studies (including the 1974 clinical study and/or 1992 follow-up visits), or on the presence
of mid-adult asthma and/or chronic bronchitis. Of the 2373 invited, 1389 (58.5%) participated by
completing a detailed questionnaire and undergoing blood sampling as well as complex lung function
and skin prick testing. The main analysis here was based on the questionnaire data collected in
2004–2008, and the measurement of post-bronchodilator (BD) spirometry for those who participated
in the clinical study between 2006 and 2008 (n = 1389). For a subset of these participants (n = 837),
additional data on history of cardiovascular events was obtained from the 2010 clinical study (see
definition of cardiovascular risk). These main components of the study design have been illustrated in
Figure 1 and in reference [39], Figure 1 on page 4.
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0 < pack-years < 15, 15 ≤ pack-years < 30 and 30 + pack-years.
Post-bronchodilator airflo obstruction (Post-B - ) as defined by FEV1/F less than the
fifth percentile of the normal predicted values (z-score < −1.645 standard deviations) following 200 µg
of salbutamol administered via spacer, and categorized according to severity [44].
ardiovascular risk as defined by an affir ative response to the question/s fro the clinical
follo -up in 2010: (1) “Has a doctor ever told you that you have/had angina, heart attack or myocardial
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infarction?” or (2) “Has a doctor ever told you that you have/had a transient ischaemic attack (TIA) or
a stroke?”
Body mass index (kg/m2) was calculated, and using World Health Organization criteria,
categorized into underweight (<18.5), normal (18.5 to <25), overweight (25 to <30) and obese
(30+) subgroups.
4.4. Cytokine Measurement
The laboratory methods have been described in detail by Kandane-Rathnayake and colleagues [45].
In brief, whole blood was collected in serum tubes, spun at 2500 rpm for 15 min and serum was stored
at −80 ◦C until the vial was thawed for testing. The average time from blood collection to processing
and freezing was 1.8 days, and the blood collection times ranged between 08:30 and 20:30 h with a peak
between 18:45 and 19:00 h. Serum levels of cytokines were measured using a high sensitivity Lincoplex
assays (LINCO Research, St. Charles, MI, USA) and Luminex Technology (Luminex Corporation,
Austin, TX, USA).
The 96-well microtitre filter plates were coated with microspheres and incubated overnight with
50 µL of standards, controls and blood serum samples. The plates were incubated with detection
antibody, which comprised a mixture of biotinylated mouse/rat anti-human cytokine antibodies
directed against each cytokine, and this was followed by streptavidin-conjugated phycoerythrin (PE).
The microspheres were resuspended in sheath fluid and the fluorescence output was read on the
Luminex instrument (Luminex Corporation, Austin, TX, USA) in eight batches.
Samples with readings below the minimum detection limit for each assay at 0.13 pg/mL were
assigned a value of half this value (0.065 pg/mL), whereas samples with readings at or above the
maximum value of 2000 pg/mL were assigned this value (2000 pg/mL). This was relevant to 5.9% and
0.3% of samples for IL-6, respectively, 0% and 3.5% for IL-8, respectively, and 0.4% and 0% for TNF-α,
respectively, so a ceiling effect was relevant for IL-8. Samples with undetectable readings were evenly
distributed between batches, and sensitivity analyses did not significantly change the results [45].
Most analyses were performed singly, and this decision was based on the results from a subset
that was measured in duplicate (n = 79). The reliability was determined by the Intraclass Correlation
Coefficient, which was above 97%, except for TNF-α (IL-6, 98.6%; IL-8, 97.7%; TNF-α, 92.7%).
Two quality controls were used for each cytokine and run in duplicate in each batch, and all were
within the expected range as coefficients of variation were less than 15%.
4.5. Statistical Analysis
All analyses were carried out using Stata (release 14SE, Stata Corporation, College Station,
TX, USA). Patient characteristics, NO2 concentrations, post-BD spirometry and serum cytokine
concentrations were compared between patients with and without post-BD-AO using chi-squared
tests for categorical variables and Wilcoxon rank sum tests for continuous variables. We examined
the association between NO2 and serum cytokines concentrations using linear regression models that
incorporated the bootstrap method to estimate robust standard errors. Cytokine concentrations were
positively skewed; therefore, values were log10 transformed in order to perform linear regression,
and results were reported as geometric mean with corresponding 95% confidence intervals. For the
cross-sectional analyses examining main effects, NO2 concentration was expressed in quartiles and
analyzed as a continuous variable if the assumption of linearity was fulfilled. For the interaction and
mediation analyses, NO2 exposure was primarily expressed as a binary variable by determined by
a cut-off between the highest and second-highest quartile (0 < NO2 < 5.8 and > 5.8 ppb), which is
roughly comparable to the 10 µg/m3 concentration used by previous meta-analyses [3,24]. Those with
missing data were excluded from individual analyses, consistent with complete case analysis.
Multivariable regression models were adjusted a priori for sex, pack-year history and smoking
status, and highest attained levels of education. Sampling weights were used a priori given the
asthma and chronic bronchitis-enrichment, where sampling weights were the inverse of the probability
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of being included in the sample, defined as the number in the strata divided by the number of
selected from each stratum. Body mass index was considered to be a potential confounder and was
included in models if the estimate changed by ≥10%. To standardize the variability of the serum
cytokine measurements, the season of study attendance and batch number were also included a priori.
The diurnal variation of IL-6 was addressed by representing Maggio and colleagues [18] with the
following approximate times of blood collection over the course of the day: 08:30–10:00 h (including
a collection at 07:55 h); 10:01–12:00 h; 12:01–13:00 h; 13:01–14:00 h; 14:01–15:00 h, 15:01–16:30 h and
16:31–20:00 h. As circulating IL-8, but not TNF-α, is also known to have diurnal variation [46], this
variable of “blood collection time” was included in the IL-8 analyses.
As potential biologically plausible effect modifiers, two-way interactions between the effects of
NO2 exposure and post-BD-AO, and the effects of NO2 and cardiovascular history were assessed with
regard to serum cytokine concentrations. Causal mediation analysis was performed using the medeff
command in Stata to assess how much of the presumed causal association between NO2 exposure
and the pro-inflammatory cytokines was mediated by post-BD-AO and/or cardiovascular history [47].
A conventional cut-off of p < 0.05 was used to determine statistical significance for all analyses.
4.6. Ethics
This study was approved by the Human Ethics Review Committees at The Universities of
Melbourne (approval number 040375), Tasmania (040375.1) and New South Wales (08094), the Alfred
Hospital (1118/04), and Royal Brisbane and Women’s Hospital Health Service District (2006/037).
Written informed consent was obtained from all participants. No project identification code has been
linked to this study as the TAHS originated in 1968.
4.7. Data Sharing
The TAHS is a cohort study with data that has been prospectively collected since 1968, and will
be an ongoing resource for future epidemiological analyses. Data collection and protocols have been
detailed in the TAHS cohort profile paper published in 2016 [39]. The raw data have not been made
widely available here, but expressions of interest can be discussed with the corresponding author,
Jennifer L. Perret and/or the principal investigator, Shyamali C. Dharmage, on an individual basis.
5. Conclusions
In a cross-sectional analysis of middle-aged adults, we have described an incremental pattern
of pollution-related responses for serum IL-6 with regard to NO2 exposure, which was not observed
for other pro-inflammatory cytokines, namely, IL-8 and TNF-α. Although case numbers were limited,
we have shown that this NO2-IL-6 relationship was neither modified nor mediated by the presence
of post-BD-AO. In contrast to this lack of influence from post-BD-AO, serum IL-6 was found to act
on cardiovascular risk, which is consistent with IL-6 being on the causal pathway between NO2 and
cardiovascular disease. While it is important to examine the cardiorespiratory effects of pollutant
co-exposures including PM2.5, overall, these findings reinforce public health recommendations to
reduce exposure to outdoor air pollutants. This includes the avoidance of combustion-derived
pollution from gasoline and diesel, industry and sources of biomass burning, which is relevant
even in low-pollution settings.
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COPD Chronic obstructive pulmonary disease
CRP C-reactive protein
CVD Cardiovascular disease
FEV1 Forced expiratory volume in one second





ppb Parts per billion
NO2 Nitrogen dioxide
PM2.5 Particulate matter less than 2.5 µm in diameter
RPM Revolutions per minute
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Figure A1. Potential representation of NO2 exposure, systemic IL-6 concentrations and its relationships 
with post-BD airflow obstruction and cardiovascular disease. 
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